In this setting, BETi re-sensitize breast cancer cells become resistant to ERBB2 inhibitor lapatinib, by suppressing the expression of alternative RTKs, including ERBB3, IGF1R, DDR1, MET, and FGFR [177]. This evidence concerns the gene ERBB2 and breast cancer.